| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors
|
Kim S.K; Lee J.M; Lee Y.W; Choi J.W; Kim H.R; Hong M.H; Haam K; Huh N; Kim J.-H; Kim Y.S; Shim H.S; Soo R.A; Shih J.-Y; Chih-Hsin CHIH-HSIN YANG; Kim M; Cho B.C.; Cho B.C.;Kim M;Chih-Hsin Chih-Hsin Yang;Shih J.-Y;Soo R.A;Shim H.S;Kim Y.S;Kim J.-H;Huh N;Haam K;Hong M.H;Kim H.R;Choi J.W;Lee Y.W;Lee J.M;Kim S.K;Pyo K.-H;Choi H.M;Kim S.-K;Lim S.M;Yun M.R; Yun M.R; Lim S.M; Kim S.-K; Choi H.M; Pyo K.-H |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors
|
Kim S.K; Lee J.M; Lee Y.W; Choi J.W; Kim H.R; Hong M.H; Haam K; Huh N; Kim J.-H; Kim Y.S; Shim H.S; Soo R.A; Shih J.-Y; Chih-Hsin CHIH-HSIN YANG; Kim M; Cho B.C.; Cho B.C.;Kim M;Chih-Hsin Chih-Hsin Yang;Shih J.-Y;Soo R.A;Shim H.S;Kim Y.S;Kim J.-H;Huh N;Haam K;Hong M.H;Kim H.R;Choi J.W;Lee Y.W;Lee J.M;Kim S.K;Pyo K.-H;Choi H.M;Kim S.-K;Lim S.M;Yun M.R; Yun M.R; Lim S.M; Kim S.-K; Choi H.M; Pyo K.-H |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study
|
Märten A; Cufer T.; Cufer T.;M?rten A;Golembesky A;Wang L;Halmos B;Gucalp R;Chih-Hsin Yang;Soo R.A;Yang C.-T;Hao D;Morabito A;Hochmair M.J; Hochmair M.J; Morabito A; Hao D; Yang C.-T; Soo R.A; CHIH-HSIN YANG; Gucalp R; Halmos B; Wang L; Golembesky A |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study
|
Märten A; Cufer T.; Cufer T.;M?rten A;Golembesky A;Wang L;Halmos B;Gucalp R;Chih-Hsin Yang;Soo R.A;Yang C.-T;Hao D;Morabito A;Hochmair M.J; Hochmair M.J; Morabito A; Hao D; Yang C.-T; Soo R.A; CHIH-HSIN YANG; Gucalp R; Halmos B; Wang L; Golembesky A |
| 臺大學術典藏 |
2020-05-26T09:26:23Z |
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study
|
Cufer T.; Märten A; Wang L; Halmos B; Gucalp R; CHIH-HSIN YANG; Soo R.A; Yang C.-T; Hao D; Hochmair M.J;Morabito A;Hao D;Yang C.-T;Soo R.A;Chih-Hsin Yang;Gucalp R;Halmos B;Wang L;M?rten A;Cufer T.; Hochmair M.J; Morabito A |
| 臺大學術典藏 |
2020-05-26T09:26:23Z |
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study
|
Cufer T.; Märten A; Wang L; Halmos B; Gucalp R; CHIH-HSIN YANG; Soo R.A; Yang C.-T; Hao D; Hochmair M.J;Morabito A;Hao D;Yang C.-T;Soo R.A;Chih-Hsin Yang;Gucalp R;Halmos B;Wang L;M?rten A;Cufer T.; Hochmair M.J; Morabito A |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos
|
Chang J.W.C; Alip A; Peters S; Douillard J.-Y.; Soo R.A; Park K; Mitsudomi T; Azrif M; CHIH-HSIN YANG; Tan D.S.W; Kim D.-W; Wu Y.-L;Planchard D;Lu S;Sun H;Yamamoto N;Kim D.-W;Tan D.S.W;Chih-Hsin Yang;Azrif M;Mitsudomi T;Park K;Soo R.A;Chang J.W.C;Alip A;Peters S;Douillard J.-Y.; Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos
|
Chang J.W.C; Alip A; Peters S; Douillard J.-Y.; Soo R.A; Park K; Mitsudomi T; Azrif M; CHIH-HSIN YANG; Tan D.S.W; Kim D.-W; Wu Y.-L;Planchard D;Lu S;Sun H;Yamamoto N;Kim D.-W;Tan D.S.W;Chih-Hsin Yang;Azrif M;Mitsudomi T;Park K;Soo R.A;Chang J.W.C;Alip A;Peters S;Douillard J.-Y.; Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N |
| 臺大學術典藏 |
2020-05-26T09:26:18Z |
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
|
Yun M.R;Choi H.M;Lee Y.W;Joo H.S;Park C.W;Choi J.W;Kim D.H;Kang H.N;Pyo K.-H;Shin E.J;Shim H.S;Soo R.A;Chih-Hsin Yang;Lee S.S;Chang H;Kim M.H;Hong M.H;Kim H.R;Cho B.C.; Yun M.R; Choi H.M; Lee Y.W; Joo H.S; Park C.W; Choi J.W; Kim D.H; Kang H.N; Pyo K.-H; Shin E.J; Shim H.S; Soo R.A; CHIH-HSIN YANG; Lee S.S; Chang H; Kim M.H; Hong M.H; Kim H.R; Cho B.C. |
| 臺大學術典藏 |
2020-05-26T09:26:18Z |
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
|
Yun M.R;Choi H.M;Lee Y.W;Joo H.S;Park C.W;Choi J.W;Kim D.H;Kang H.N;Pyo K.-H;Shin E.J;Shim H.S;Soo R.A;Chih-Hsin Yang;Lee S.S;Chang H;Kim M.H;Hong M.H;Kim H.R;Cho B.C.; Yun M.R; Choi H.M; Lee Y.W; Joo H.S; Park C.W; Choi J.W; Kim D.H; Kang H.N; Pyo K.-H; Shin E.J; Shim H.S; Soo R.A; CHIH-HSIN YANG; Lee S.S; Chang H; Kim M.H; Hong M.H; Kim H.R; Cho B.C. |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)
|
Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgee S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Camidge D.R. |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
|
Viteri S; Chang G.-C; Chiari R; Cho B.C; Ciardiello F; Curigliano G; Hida T; Lee D.H; Lim W.T.D; Chia-Chi Lin; Martinez A; Murakami H; Natsume I; Nishio M; Paz-Ares L; Soo R.A; Cattan V; Gandossi E; Heck H; Park K. |
| 臺大學術典藏 |
2020-05-25T07:35:08Z |
Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
|
Solomon B.J; Martini J.-F; Ou S.-H.I; Chiari R; Soo R.A; Bearz A; Li S; Thurm H; Chia-Chi Lin; Riely G.J; Bauer T.M; Shaw A.T. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non�Vsmall-cell lung cancer
|
Shaw A.T; Solomon B.J; Besse B; Bauer T.M; Chia-Chi Lin; Soo R.A; Riely G.J; Ignatius Ou S.-H; Clancy J.S; Li S; Abbattista A; Thurm H; Satouchi M; Camidge D.R; Kao S; Chiari R; Gadgeel S.M; Felip E; Martini J.-F. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
|
Solomon B.J; Shaw A.T.; Ignatius Ou S.-H; Thurm H; Peltz G; Besse B; Bauer T.M; Felip E; Soo R.A; Camidge D.R; Chiari R; Bearz A; Chia-Chi Lin; Gadgeel S.M; Riely G.J; Tan E.H; Seto T; James L.P; Clancy J.S; Abbattista A; Martini J.-F; Chen J |
| 臺大學術典藏 |
2020-05-25T07:34:59Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgeel S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Peltz G; Ross Camidge D. |
| 臺大學術典藏 |
2020 |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Yang F.; Tan D.S.W; Mok T.S.K; Ahn M.-J; Onishi H; Ahn Y.C; Soo R.A; Kim D.-W; Yang J.C; Reungwetwattana T; Ho G.F; Yang F.;Tan D.S.W;Mok T.S.K;Ahn M.-J;Onishi H;Ahn Y.C;Soo R.A;Kim D.-W;Yang J.C;Reungwetwattana T;Ho G.F;Chan A.W;Tho L.M;Lee V.H.F;Chia-Chi Lin;Chua K.L.M;Tan W.L; Tan W.L; Chua K.L.M; Chia-Chi Lin; Lee V.H.F; Tho L.M; Chan A.W |
| 臺大學術典藏 |
2020 |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Yang F.; Tan D.S.W; Mok T.S.K; Ahn M.-J; Onishi H; Ahn Y.C; Soo R.A; Kim D.-W; Yang J.C; Reungwetwattana T; Ho G.F; Yang F.;Tan D.S.W;Mok T.S.K;Ahn M.-J;Onishi H;Ahn Y.C;Soo R.A;Kim D.-W;Yang J.C;Reungwetwattana T;Ho G.F;Chan A.W;Tho L.M;Lee V.H.F;Chia-Chi Lin;Chua K.L.M;Tan W.L; Tan W.L; Chua K.L.M; Chia-Chi Lin; Lee V.H.F; Tho L.M; Chan A.W |
| 臺大學術典藏 |
2019 |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial
|
Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I. |
| 臺大學術典藏 |
2019 |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial
|
Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I. |
